JP2024510207A - Kras阻害剤 - Google Patents

Kras阻害剤 Download PDF

Info

Publication number
JP2024510207A
JP2024510207A JP2023555534A JP2023555534A JP2024510207A JP 2024510207 A JP2024510207 A JP 2024510207A JP 2023555534 A JP2023555534 A JP 2023555534A JP 2023555534 A JP2023555534 A JP 2023555534A JP 2024510207 A JP2024510207 A JP 2024510207A
Authority
JP
Japan
Prior art keywords
diazabicyclo
methoxy
fluoro
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510207A5 (cg-RX-API-DMAC7.html
Inventor
エドワード フィンク,ブライアン
ジョセフ チャーニー,ロバート
グ,ケヒョン
ベラパルチ,アッペンダー
デイビッド バッカロ,ウェイン
ルアン,ジェミン
チン,ラン-イン
エス シルデ,プラビン
ラーマン,ハシブル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024510207A publication Critical patent/JP2024510207A/ja
Publication of JP2024510207A5 publication Critical patent/JP2024510207A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023555534A 2021-03-12 2022-03-14 Kras阻害剤 Pending JP2024510207A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163160436P 2021-03-12 2021-03-12
US63/160,436 2021-03-12
US202163288965P 2021-12-13 2021-12-13
US63/288,965 2021-12-13
PCT/US2022/020230 WO2022192790A1 (en) 2021-03-12 2022-03-14 Kras inhibitors

Publications (2)

Publication Number Publication Date
JP2024510207A true JP2024510207A (ja) 2024-03-06
JP2024510207A5 JP2024510207A5 (cg-RX-API-DMAC7.html) 2025-03-25

Family

ID=81074021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555534A Pending JP2024510207A (ja) 2021-03-12 2022-03-14 Kras阻害剤

Country Status (11)

Country Link
US (1) US20240217982A1 (cg-RX-API-DMAC7.html)
EP (1) EP4305037B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510207A (cg-RX-API-DMAC7.html)
KR (1) KR20230169968A (cg-RX-API-DMAC7.html)
AU (1) AU2022232460A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210383A1 (cg-RX-API-DMAC7.html)
ES (1) ES3014892T3 (cg-RX-API-DMAC7.html)
IL (1) IL305572A (cg-RX-API-DMAC7.html)
MX (1) MX2023010429A (cg-RX-API-DMAC7.html)
WO (1) WO2022192790A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517695A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023179629A1 (zh) * 2022-03-22 2023-09-28 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
CN118344386A (zh) * 2023-01-13 2024-07-16 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
WO2023183585A1 (en) * 2022-03-25 2023-09-28 Eli Lilly And Company Kras inhibitors
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
EP4631942A1 (en) 2022-10-21 2025-10-15 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Pan-kras degrading agent, and preparation method therefor and use thereof
CN117917416A (zh) 2022-10-21 2024-04-23 上海领泰生物医药科技有限公司 Kras g12d降解剂及其制备方法和应用
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JP2020521742A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Krasの共有結合性阻害剤
WO2021031952A1 (zh) * 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
JP2024506329A (ja) * 2021-02-09 2024-02-13 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JP2020521742A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Krasの共有結合性阻害剤
WO2021031952A1 (zh) * 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
JP2024506329A (ja) * 2021-02-09 2024-02-13 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517695A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法

Also Published As

Publication number Publication date
EP4305037B1 (en) 2025-02-26
MX2023010429A (es) 2023-09-12
AU2022232460A1 (en) 2023-09-14
WO2022192790A1 (en) 2022-09-15
ES3014892T3 (en) 2025-04-28
KR20230169968A (ko) 2023-12-18
IL305572A (en) 2023-10-01
US20240217982A1 (en) 2024-07-04
CA3210383A1 (en) 2022-09-15
BR112023017661A2 (pt) 2023-12-05
EP4305037A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
ES3014892T3 (en) Kras inhibitors
JP2024510606A (ja) Kras g12d阻害剤
TWI851557B (zh) 藥學化合物
TWI719437B (zh) Mat2a之雜雙環抑制劑及治療癌症之使用方法
WO2024054926A1 (en) Kras g12d inhibitors
WO2023225302A1 (en) Aza-tetracyclic oxazepine compounds and uses thereof
CN119841847A (zh) 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
CN118647620A (zh) 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
JP2022505075A (ja) SMARCA2及び/又はSMARCA4のディグレーダーとしてのタンパク質分解誘導キメラ(Protac)
CN108349996B (zh) 三环pi3k抑制剂化合物及其使用方法
JP2017511801A (ja) BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体
TWI840343B (zh) AhR調節劑
EP4284804A1 (en) Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
CN119923398A (zh) 环状化合物和其使用方法
WO2024046420A1 (zh) 稠合二环类化合物、其制备方法及其在医药上的应用
WO2025059027A1 (en) Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
CN117242074A (zh) Kras g12d抑制剂
CN117120442A (zh) 用于治疗癌症、自身免疫性病症和炎性病症的三环化合物
TW202300150A (zh) 環狀化合物及其使用方法
EA050560B1 (ru) Ингибиторы kras
EA050518B1 (ru) Ингибиторы kras g12d
CN117120447A (zh) 环状化合物和其使用方法
TW202229281A (zh) 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
HK1258849B (en) Tricyclic pi3k inhibitor compounds and methods of use
HK1211929A1 (en) Benzoxazepin pi3k inhibitor compounds and methods of use

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508